Curated News
By: NewsRamp Editorial Staff
February 17, 2025

GeoVax Labs to Present Update on Mpox Vaccine Program at Emerging Growth Conference

Reddit Discuss on RedditDiscuss on LinkedIn LinkedInDiscuss on Substack SubstackDiscuss on Telegram TelegramView History of this news story on GitHub Github
Source News Release

TLDR

  • GeoVax Labs, Inc. to present at Emerging Growth Conference to discuss GEO-MVA vaccine for Mpox and smallpox, gaining insights into innovative immunotherapy.
  • GeoVax's lead clinical program, GEO-CM04S1, focuses on COVID-19 vaccine development with Phase 2 trials underway for various patient populations.
  • GeoVax's efforts in developing vaccines and therapies for infectious diseases and cancers aim to improve global health outcomes and treatment options.
  • Learn about GeoVax's novel vaccines for infectious diseases and solid tumor cancers, offering hope for improved immunotherapies and disease treatments.

Impact - Why it Matters

This news matters as it provides insight into the latest developments in GeoVax Labs' vaccine program, including updates on GEO-MVA for Mpox and smallpox. Shareholders and the investment community will have the opportunity to interact with the company's CEO, David Dodd, and gain valuable information on the company's progress in developing novel vaccines for infectious diseases and cancers.

Summary

GeoVax Labs, Inc. will be presenting at the Emerging Growth Conference to provide an update on its vaccine program, focusing on the development of GEO-MVA for Mpox and smallpox. The company's Chairman and CEO, David Dodd, will be leading the presentation and addressing questions from shareholders and the investment community.

GeoVax is a biotechnology company specializing in immunotherapies and vaccines for infectious diseases and cancers. The company's lead clinical program includes a next-generation COVID-19 vaccine, GEO-CM04S1, which is currently undergoing Phase 2 clinical trials. Additionally, GeoVax is evaluating Gedeptin®, an oncolytic solid tumor gene-directed therapy, in clinical trials for head and neck cancers.

Source Statement

This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, GeoVax Labs to Present Update on Mpox Vaccine Program at Emerging Growth Conference

blockchain registration record for the source press release.